T细胞非霍奇金淋巴瘤CCR7、MMP-9及VEGF表达意义初探  

Pilot Study of Expression of CCR7,MMP-9 and VEGF in T-Cell Non-Hodgkin’s Lymphoma

作　　者：王晟怡[1] 赵国范[1] 杨晶[1] 白雪[1] 张云霄[1] 许秀丽[1] 

机构地区：[1]天津医科大学病理学教研室,300070

出　　处：《天津医药》2010年第5期360-362,449,共4页Tianjin Medical Journal

基　　金：天津市高等学校科技发展基金资助项目(项目编号:20050110)

摘　　要：目的:探讨趋化因子受体-7(CCR7)、基质金属蛋白酶(MMP)-9及血管内皮生长因子(VEGF)在T细胞非霍奇金淋巴瘤(T-NHL)中的表达及其临床意义。方法:收集41例T-NHL(T-NHL组)及19例反应性增生淋巴结(对照组)标本及其临床病理资料,应用免疫组织化学染色检测CCR7、MMP-9及VEGF的表达,并分析其表达与临床病理指标之间的关系。结果:CCR7、MMP-9及VEGF在T-NHL组中的高表达率分别为82.9%、87.8%及51.2%,均高于其在反应性增生淋巴结组织中的高表达率,差异具有统计学意义(均P<0.01)。多部位发生T-NHL患者CCR7、MMP-9的高表达率高于单部位发生患者,差异有统计学意义(均P<0.05)。CCR7、MMP-9及VEGF的表达之间无明显相关性(均P>0.05)。结论:T-NHL中存在CCR7、MMP-9及VEGF的高表达,这些指标的高表达对于提示预后较差具有一定的价值。Objective： To investigate the expression and clinical significance of chemokine receptor-7 （CCR7）,matrix metalloproteinase9 （MMP-9） and vascular endothelial growth factor （VEGF）in T-cell non-Hodgkin’s lymphoma （T-NHL）.Methods： Specimens of 41 T-NHL cases （T-NHL group） and 19 reactive lymphoid hyperplasia cases （control group）were collected along with their clinicopathologic data.The expressions of CCR7,MMP-9 and VEGF were detected using immunohistochemical staining and were then used to study the correlation between the expression and clinicopathologic factors.Results： The expressions of CCR7,MMP-9 and VEGF were significantly higher in T-NHL group than those of control （P 0.01）,and the overexpression rates were 82.9%,87.8% and 51.2%,respectively.The overexpression rates of CCR7 and MMP-9 were found more in patients with more lesions than those in patients with single lesion （P 0.05）.There was no correlation between the expressions of CCR7,MMP-9 and VEGF （P 0.05）.Conclusion： Overexpressions of CCR7,MMP-9 and VEGF were detected in T-NHL,which may be the unfavorable factors influencing prognosis of T-NHL patients.

关 键 词：淋巴瘤 非霍奇金 受体 趋化因子 基质金属蛋白酶9 血管内皮生长因子类 预后 

分 类 号：R734.2[医药卫生—肿瘤]